

LivaNova PLC: Transaction In Own Shares And Total Voting Rights - Correction

September 23, 2016 9:30 AM ET

23 September 2016

TRANSACTION IN OWN SHARES AND TOTAL VOTING RIGHTS - CORRECTION

LivaNova PLC (the “Company” or “LivaNova”) announces on 23 September 2016, that it was notified today that it incorrectly notified the total number of ordinary shares repurchased as set out in the announcement on 23 September 2016 at 7:00 am (BST). The Company repurchased 10,000 ordinary shares on 22 September 2016 but due to a scrivener error, the Company incorrectly stated that after giving effect to the cancellation of these ordinary shares, the number of shares of ordinary shares outstanding would be 49,983,009 and the total number of voting rights in the Company would be 49,983,009.

In fact, after giving effect to the cancellation of the repurchased shares, the correct number of ordinary shares outstanding would be ~~49~~48,983,009 and the total number of voting rights in the Company would be ~~49~~48,983,009. Shareholders may use these corrected figures as the denominator for the calculations by which they will determine if they are required to notify their interest in or a change to their interest in the Company under the FCA’s Disclosure Guidance and Transparency Rules.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media

Karen King

Vice President, Investor Relations & Corporate Communications

Phone: +1 (281) 228-7262

Fax: +1 (281) 218-9332

e-mail: corporate.communications@livanova.com